Chile

Chile's psychedelics landscape is tightly controlled and research-led rather than access-oriented. The legal framework centres on Law No.

Ask Blossom about this country

Data updated May 18, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inChile.

1
Chile's psychedelic activity is concentrated in regulated medicine and research rather than routine public access.
2
The strongest near-term clinical signal is ketamine, which is consistent with Blossom's linked-compound profile and with the country's existing psychiatric and pain-use ecosystem.
3
The national regulator's role in narcotics and psychotropics suggests that any future psychedelic access would likely remain permission-based and closely supervised.
4
The absence of linked active trials in Blossom is consistent with a small public-facing Chilean psychedelic research footprint that is not yet visible in major trial signals from this scan.
5
Recent official material continues to frame psychedelics-related substances through controlled-substance enforcement and medicines oversight rather than liberalised access.

Research and Access Snapshot

Blossom currently tracks 1 psychedelic clinical trial connected to Chile.

Active trials: 0
Total trials: 1
Stakeholders: 1
Events: 0

Top Compounds

Ketamine(1)

Medical Access

Chile maintains a controlled-substances regulatory framework (Ley N°20.000) that generally classifies classical psychedelic compounds (psilocybin, MDMA, DMT, mescaline, 2C-series, 5-MeO-DMT, ibogaine) as controlled, with no routine public reimbursement outside authorized research. Ketamine is a registered anesthetic and is widely used clinically (including growing private-sector off-label psychiatric programs); esketamine (Spravato) has a commercial registration and is available under medical supervision but access and public reimbursement are limited...

View trials→View stakeholders→Open access guide→

Regulatory Status

Chile maintains a medical-only, tightly controlled framework for psychedelic and related substances. Unauthorised manufacture, possession, trafficking or facilitation of controlled narcotic or psychotropic substances is prohibited under Law No. 20,000, while the controlled list is defined by regulation; psilocybin, MDMA, DMT, mescaline, 2C-series compounds, 5-MeO-DMT and ibogaine should be treated as controlled unless a specific authorised research or regulatory pathway is documented. Ketamine is a registered medicine used clinically, and esketamine has an established regulatory presence, but broader patient access and public reimbursement appear limited and should be verified case by case.